1. Escudier B, Eisen T, Stadler WM et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. PMID: 19451442.
2. Motzer RA, Hutson TE, Tomczac P et al. Overall survival and updated results for sunitinib compared with interferon (IFN)-alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. PMID: 19487381.
3. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103–11.
4. Escudier BJ, Bellmunt J, Negrier S et al. Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-a2a (IFN) in metastatic renal cell carcinoma (mRCC). J Clin Oncol 2009; 27: 15s suppl.; abstr. 5020.
5. Rini BI, Halabi S, Rosenberg JE et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: calgb 90206. J Clin Oncol 2008; 26: 5422–8.
6. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449–56.
7. Motzer RJ, Bacik J, Mariani T et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of nonclear-cell histology. J Clin Oncol 2002; 20: 2376–81.
8. Dutcher JP, de Souza PL, Figlin R et al. Effect of temsirolimus versus interferon-a on survival of patients with advanced renal cell carcinoma of different tumour histologies. ASCO GI 2008. <http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&amp;vmview=abst_detail_view&am... accessed 15.05.09.
9. Motzer RJ, Bacik J, Mariani T et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002; 20: 2376–81.
10. Motzer RJ, Mazumdar M, Bacik J et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17: 2530–40.
11. Escudier B, Szczylik C, Hutson TE et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 1280–9.
12. Beck J, Bajetta E, Escudier B et al. A large open-label, non-comparative, phase III study of the multi-targeted kinase inhibitor sorafenib in European patients with advanced renal cell carcinoma. Presentation at ECCO 14 2007, Barcelona, Spain; 2007.
13. Henderson CA, Bukowski RM, Stadler WM, et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: subset analysis of patients (pts) with brain metastases (BM). J Clin Oncol 2007; 25 (Suppl.): 650s Abstract 15506.
14. Gore ME, Porta C, Oudard S et al. Sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment of toxicity in an expanded access trial with subpopulation analysis. Presentation at ASCO 2007, Chicago, IL, USA. <http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&amp;vmview=abst_detail_view&am...; 2009 accessed 15.05.09.
15. Hariharan S, Szczylik C, Bracarda S et al. Sunitinib in metastatic renal cell carcinoma (mRCC) patients (pts) with brain metastases (mets): data from an expanded access trial. Presentation at ASCO 2008, Chicago, IL, USA. <http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&amp;vmview=abst_detail_view&am...; 2008 accessed 15.05.09.
16. Massard C, Zonierek J, Laplanche A et al. Incidence of brain metastasis in advanced renal cell carcinoma among patients randomized in a phase III trial of sorafenib, an oral multi-kinase inhibitor. In: Poster presentation at ESMO 2006, Istanbul, Turkey; 2006 (Abstr) 454P.
17. Motzer RJ, Figlin RA, Hutson TE et al. Sunitinib versus interferon-alfa (IFN-a) as first-line treatment of metastatic renal cell carcinoma (mRCC): updated results and analysis of prognostic factors. Presentation at ASCO 2007, Chicago, IL, USA. <http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts? &vmview=abst_detail_view&confID=47&abstractID=32015>; 2009 accessed 15.05.09.
18. Heng DY, Xie W, Regan M et al. Prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (RCC) treated with vascular endothelial growth factor (VEGF)-targeted agents: results from a large multicenter study. Presentation at ASCO Genitourinary Cancers Symposium 2009.
19. Bellmunt J, Negrier S, Escudier B et al. The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG taskforce. Crit Rev Oncol Hematol 2099; 69: 64–72.
20. Bajetta E, Ravaud A, Bracada S et al. Efficacy and safety of first-line bevacizumab (BEV) plus interferon-a2a (IFN) in patients (pts) >65 years with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2008; 26 (Suppl.): 273s (Abstr): 5095.
20. Choueiri TK, Garcia JA, Elson P et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 2007; 110: 543–50.
21. Dutcher JP, Szczylik C, Tannir N et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN). Presentation at ASCO 2007; Chicago, IL, USA. http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&amp;vmview=abst_detail_view&am...; 2009 accessed 15.05.09.
22. Corbergh JW, Janssen-Heijnen ML, Post PN, Razenberg PP. Serious co-morbidity among unselected cancer patients mewly diagnosed in the southeasten tart of The Netherlands in 1993–1996. J Clin Epidemil 1999; 52: 1131–6.
23. Escudier B, Eisen t, Stadler WM et al. Sorafenib in advanced clear-cell ranal-cell carcinoma. N engl J Med 2007; 356: 125–34.
24. Nexavar summary of product characteristics. <http://www.emea.europa.eu/humandocs/PDFs/EPAR/nexavar/H-690-PI-en.pdf&gt;; 2009 accessed 15.05.09.
25. Sutent summary of product characteristics. <http://www.emea.europa.eu/humandocs/PDFs/EPAR/sutent/H-687-PI-en.pdf&gt;; 2009 accessed 15.05.09.
26. Avastin summary of product characteristics. <http://www.emea.europa.eu/humandocs/PDFs/EPAR/avastin/H-582-PI-en.pdf&gt;; 2009 accessed 15.05.2009.
27. Grunwald V, Heinzer H, Fiedler W. Managing side effects of angiogenesis inhibitors in renal cell carcinoma. Onkologie 2007; 30: 519–24.
28. Maroto-Rey P, Villavincencio H. Sorafenib: tolerance in patients on chronic haemodialysis. Oncology 2008; 74: 245–6.
29. Khosravan R, Toh M, LaFargue J, Ni G, Bello C. Sunitinib pharmacokinetic (PK) and safety data in subjects with renal impairment and on hemodialysis. J Clin Oncol 2008; 26 (Suppl.): 131s (Abstract): 2578.
30. Rathmell K, Amin C, Wallen E, Pruthi R. Neoadjuvant therapy with sorafenib for locally advanced renal cell carcinoma (RCC). ASCO GU 2008. <http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&amp;vmview=abst_detail_view&am...; 2009 accessed 15.05.09.
31. Rini BI. Clinical prognostic and predictive markers for metastatic RCC therapeutic choices. Presentation at ASCO 2008, Chicago, IL, USA. <http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&amp;vmview=vm_session_presenta...; 209 accessed 15.05.09. Cancer Treatment Reviews (2009)

И.В.Поддубная

Кафедра онкологии ГОУ ДПО РМАПО, Москва